Skip to main content

Day: January 15, 2024

Form 8.3 – [LONDONMETRIC PROPERTY PLC – 12 01 2024] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LONDONMETRIC PROPERTY PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

Form 8.3 – [abrdn EUROPEAN LOGISTICS INCOME PLC – 12 01 2024] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree abrdn EUROPEAN LOGISTICS INCOME PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Stabilisation transactions with AS Infortar shares – end of stabilisation period notice

This notice is published with reference to the initial public offering of the shares of AS Infortar (“Infortar”) and should be read in conjunction with Infortar’s public offering, listing and admission to trading prospectus dated 24 November 2023 (the “Prospectus”), together with Infortar’s notification on the results of the initial public offering of its shares and final price dated 11 December 2023. Infortar informs that during the Stabilisation Period from 14 December 2023 to 13 January 2024 the following stabilisation measures on following conditions were carried out by Swedbank AS as the Stabilising Arranger: Company: AS InfortarSecurities: INFORTAR LIHTAKTSIA, ISIN code: EE3100149394Ticker: INF1TStabilising Arranger: Swedbank ASTrading Venue: Nasdaq Tallinn Stock ExchangeStabilisation Period Start Date: 14 December...

Continue reading

Information on Šiaulių Bankas Strategy Update 2024 – 2029

On 15 January 2024 Šiaulių Bankas AB announce its Strategy Update for 2024-2029 at the Investors Webinar, outlining its strategic ambition to become the best bank in Lithuania by 2029. The bank is committed to achieving this goal by delivering an exceptional customer experience, fostering top-of-mind recognition among Lithuanian banking clients, expanding its customer base and loan portfolio at a faster pace than the market, and generating mid-to-high teen return on equity. “To achieve our ambitious goals, we are embarking on a strategic transformation. Our vision is to become the bank key stakeholders choose to grow with, including clients, employees and investors. After completion of the merger of the retail businesses with INVL, we are ready to move forward even faster. Our major shareholders, including Lithuanian and global business...

Continue reading

Urology Devices Market Set to Soar Past USD 58.80 Billion by 2030

The global Urology Devices market size is expected to reach USD 58.80 billion by 2030 and exhibit a CAGR of 4.8% in the forecast period (2023−2030), according to Skyquest’s latest research report. The aging global population is increasing the incidence of urological conditions such as kidney stones, urinary incontinence, and benign prostatic hyperplasia (BPH). Advances in medical technology and minimally invasive surgical techniques have led to the development of innovative urology devices, attracting both patients and healthcare providers is fueling the market’s growth. Westford USA, Jan. 15, 2024 (GLOBE NEWSWIRE) — According to SkyQuest’s latest global research of the Urology Devices market, increasing adoption of telemedicine and remote monitoring solutions for urological conditions enhances patient care and...

Continue reading

AGF Private Capital Inc. to Make Strategic Investment in Kensington Capital Partners Limited

Investment further expands AGF’s presence in the private markets with a proven private equity investment firm with $2.6B of assets under management while accelerating Kensington’s growth and distribution reach TORONTO, Jan. 15, 2024 (GLOBE NEWSWIRE) — AGF Private Capital Inc. – AGF Management Limited’s (AGF) private markets business – has signed definitive agreements to acquire a majority interest in Kensington Capital Partners Limited (Kensington), one of Canada’s leading alternative investment firms, as part of AGF’s strategic imperative to grow its private markets business. Founded in 1996, Kensington has $2.6 billion in assets under management and an impressive 27-year history of successful performance and growth. The 40-member team has a proven track record of success managing private equity investments across mid-market...

Continue reading

Extendicare Announces January 2024 Dividend of C$0.04 per Share

MARKHAM, Ontario, Jan. 15, 2024 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common Share”) for the month of January 2024, which is payable on February 15, 2024 to shareholders of record at the close of business on January 31, 2024. This dividend is designated as an “eligible dividend” within the meaning of the Income Tax Act (Canada). About Extendicare Extendicare is a leading provider of care and services for seniors across Canada, operating under the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network brands. We are committed to delivering quality care throughout the health continuum to meet the needs of a growing seniors population. We operate or provide managed services...

Continue reading

Corporate Wellness Market Size Worth USD 81.19 Billion in 2032 | Emergen Research

Increasing prevalence of chronic diseases, reduction in employee healthcare costs, and rising number of deskbound job profiles are key factors driving corporate wellness market revenue growth. Vancouver, Jan. 15, 2024 (GLOBE NEWSWIRE) — The global corporate wellness market size was USD 53.04 Billion in 2022 and is expected to register a rapid revenue CAGR of 4.3% during the forecast period. Increasing prevalence of chronic diseases, reduction in employee healthcare costs, and rising number of deskbound job profiles are key factors driving market revenue growth. Corporate wellness initiatives encompass a range of policies, programs, and benefits to tackle various health risks and conditions, impacting both employees and organization. According to National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), in the...

Continue reading

Aptamers Market Size Worth USD 13.5 Billion in 2032 | Emergen Research

Increasing investments in aptamer Research & Development (R&D) and rapid technological advancements in aptamers are key factors driving aptamers market revenue growth. Vancouver, Jan. 15, 2024 (GLOBE NEWSWIRE) — The global aptamers market size was USD 1.80 Billion in 2022 and is expected to register a rapid revenue CAGR of 24.22% during the forecast period. Increasing investments in aptamer Research & Development (R&D) and rapid technological advancements in aptamers are key factors driving market revenue growth. Increasing prevalence of chronic disease is another key factor driving revenue growth of the market. World Health Organization (WHO) estimated that 71% individuals died globally due to chronic disease. Over 7 out of 10 deaths are caused by chronic diseases, such as heart disease, stroke, cancer, diabetes,...

Continue reading

High Throughput Screening Market Size Worth USD 33.20 Billion in 2032 | Emergen Research

Rising need for diverse compound libraries are major factors driving High Throughput Screening market revenue growth. Vancouver, Jan. 15, 2024 (GLOBE NEWSWIRE) — The global high throughput screening market size was USD 23.20 Billion in 2022 and is expected to register a revenue CAGR of 3.2% during the forecast period. Increasing funding for Research & Development (R&D), regulatory support for innovative approaches, and rising need for diverse compound libraries are major factors driving market revenue growth. The advancements in automation and robotics, focus on personalized medicine, and efficiency in drug discovery are among other key factors contributing to market revenue growth. Automated systems are streamlining the screening process, enabling rapid and efficient analysis of large compound libraries, thus significantly...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.